Latest news with #salesgrowth
Reuters
2 days ago
- Automotive
- Reuters
Autoliv hikes sales forecast as tariff costs shift to automakers
STOCKHOLM, July 18 (Reuters) - Swedish auto supplier Autoliv (ALV.N), opens new tab, raised its full-year sales guidance on Friday and said it had passed on most of its tariff-related costs in the second quarter, as it reported a profit for the period that matched expectations. The world's largest maker of airbags and seat belts is mostly affected by tariffs between the United States and Mexico and Canada. U.S. President Donald Trump has threatened to raise tariffs on imports from both of these countries to 30% and 35%, respectively, from August. U.S. tariffs on foreign auto imports are expected to raise car prices by thousands of dollars, reducing demand and hurting job growth, rattling an industry already struggling with a difficult transition to electric vehicles. "We recovered around 80% of tariff costs in the second quarter, and we expect to recover most of what remains later in the year," CEO Mikael Bratt said, adding that the company remained confident it could continue to successfully receive compensation from its customers for tariffs. "There's no logic whatsoever why the suppliers or the value chain should absorb this," he added. Autoliv - customers of which include most of the largest automakers such as Volkswagen, Stellantis and Toyota - said it now sees organic sales growth this year of around 3%. Its previous forecast, last reiterated in April, was for 2%. Analysts at Jefferies said in a note to clients that the results again demonstrated Autoliv's resilience in a quarter with significant tariff volatility. Adjusted operating profit grew in line with expectations to $251 million from a year-earlier $221 million, with organic sales growth of 3%. Its adjusted operating margin was 9.1%, a near industry-leading margin, according to analysts at Citi.
Yahoo
2 days ago
- Business
- Yahoo
Saab Q2 2025 results: Accelerating growth and strengthening our market position
STOCKHOLM, July 18, 2025 /PRNewswire/ -- Saab presents the results for January-June 2025. "We are strengthening our market position and see a continued large interest in our products and solutions. Saab's sales growth is high and we continue to invest to build capacity and meet long-term strong demand from the defence sector. At the same time, we continue to deliver strong profitability," says Micael Johansson, President and CEO, Saab. Key highlights Q2 2025 Order intake for the second quarter amounted to SEK 28,403m (39,574), driven by strong growth in small and medium-sized orders. Sales in the quarter amounted to SEK 19,786m (15,170) and corresponded to an organic sales growth of 32% (21). All business areas reported sales growth, with particularly strong growth in Dynamics of 73% in the quarter. EBITDA amounted to SEK 2,831m (1,961) and corresponded to an EBITDA margin of 14.3% (12.9) in the quarter. EBIT increased 49% and amounted to SEK 1,977m (1,331), corresponding to a margin of 10.0% (8.8). In the quarter, a non-recurring contribution of SEK 105m in the minority portfolio had a positive effect on EBIT. Net income increased to SEK 1,536m (1,012) and earnings per share amounted to SEK 2.83 (1.85), an increase of 53%. Operational cash flow amounted to SEK -1,136m (-2,251), and mainly reflected continued investments for capacity build-up. Net liquidity position was SEK 690m (-2,354) at the end of the period. Outlook for 2025: organic sales growth between 16-20%, compared to previous organic sales growth between 12-16%. Reiterating EBIT growth higher than the organic sales growth and positive operational cash flow for the full year. Presentation of Saab's Q2 2025 results Saab's President and CEO Micael Johansson and CFO Anna Wijkander will present the results. Date: Friday 18 July at 10.00 a.m. (CEST). You are welcome to watch the live webcast or dial in to the conference call. It is possible to submit questions over the conference call and from the webcast page. Live webcast: Registration for conference call: The interim report, presentation material and webcast will be published on ContactsMattias RådströmHead of Media Relations +46 (0)734 180 018presscentre@ Merton KaplanHead of Investor Relations+46 (0)734 182 Saab is a leading defence and security company with an enduring mission, to help nations keep their people and society safe. Empowered by its 25,000 talented people, Saab constantly pushes the boundaries of technology to create a safer, more sustainable and more equitable world. Saab designs, manufactures and maintains advanced systems in aeronautics, weapons, command and control, sensors and underwater systems. Saab is headquartered in Sweden. It has major operations all over the world and is part of the domestic defence capability of several nations. The information is such that Saab AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, on 18 July 2025 at 07.30 (CEST). This information was brought to you by Cision The following files are available for download: Saab Q2 2025 results - Accelerating growth and strengthening our market position Micael Johansson close-up Micael Johansson Saab Q2 2025 results - press release View original content: SOURCE Saab
Yahoo
3 days ago
- Business
- Yahoo
Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors
Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still plummeted nearly 10% after management dialed back earnings and growth projections for the rest of the year. The company reported second-quarter sales of $11.14 billion, beating the consensus of $11.07 billion. Second-quarter sales increased 7.4% on a reported basis, 6.9% on an organic basis, or 7.5% when excluding COVID-19 testing-related U.S. MedTech giant reported adjusted earnings of $1.26, beating the consensus of $1.25, and within the management guidance of $1.23-$1.27. 'Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline,' said Robert B. Ford, chairman and chief executive officer, Abbott. 'We see this momentum carrying into 2026.' Medical Devices sales increased 13.4% on a reported basis and 12.2% on an organic basis to $5.37 billion. Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology. Several products contributed to the performance, including FreeStyle Libre, Navitor, TriClip, and AVEIR. In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4% on a reported basis and 19.6% organically. Worldwide Nutrition sales increased 2.9% (+3.4% on an organic basis) to $2.21 billion. View more earnings on ABT Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1% (+6.6% on an organic basis), led by strong growth of Ensure and Glucerna. Global Diagnostics sales decreased 1% (-1.4% on an organic basis) and increased 0.8% when excluding COVID-19 testing-related sales. The year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China impacted diagnostics sales growth. COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million a year ago. Established Pharmaceuticals sales increased 6.9% (+7.7% on an organic basis) to $1.38 billion. Abbott's reported operating margin of 18.4%, with an adjusted operating margin of 22.9%, which reflects a 100 basis point increase. Guidance Abbott narrowed full-year 2025 adjusted earnings guidance from $5.05-$5.25 per share to $5.10-$5.20 per share compared to the consensus of $5.16. The company expects organic sales growth of 7.5%-8.0% compared to prior guidance of 7.5%-8.5%, or 6.0% to 7.0% when including COVID-19 testing-related sales. Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%. Abbott expected third-quarter 2025 adjusted earnings of $1.28-$1.32 per share, compared to the consensus of $1.34 per share. During the earnings conference call, an Abbott executive addressed the impact of tariffs, reporting that the estimated headwind has been revised down to $200 million for the year, lower than previous estimates. Price Action: ABT stock is trading lower by 8.00% to $121.21 at last check Thursday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ABBOTT LABORATORIES (ABT): Free Stock Analysis Report This article Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
3 days ago
- Business
- Yahoo
Abbott Reports Second-Quarter 2025 Results
Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1 Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26 Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increase Reported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increase ABBOTT PARK, Ill., July 17, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2025. Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1. Second-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.26, which excludes specified items and reflects double-digit growth compared to the prior year. First-half sales increased 5.7 percent on a reported basis, 6.9 percent on an organic basis, or 7.9 percent when excluding COVID-19 testing-related sales2. Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales. Abbott projects full-year 2025 adjusted diluted EPS of $5.10 to $5.20, which reflects double-digit growth at the midpoint. In April, Abbott completed enrollment ahead of schedule in its FlexPulse U.S. IDE trial, which is designed to evaluate the TactiFlex™ Duo Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib). In April, Abbott announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) clinical feasibility study. This study was the world's first assessment of a leadless pacemaker delivering conduction pacing, which produces pacing that closely mimics the heart's natural electrical rhythm and represents a new treatment option for people with irregular heart rhythms. In May, Abbott announced U.S. Food and Drug Administration (FDA) approval of the company's Tendyne™ transcatheter mitral valve replacement (TMVR) system, a first-of-its-kind device to help treat people with mitral valve disease. Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia to be completed by 2028. "Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline," said Robert B. Ford, chairman and chief executive officer, Abbott. "We see this momentum carrying into 2026." SECOND-QUARTER BUSINESS OVERVIEWManagement believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase. Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. Second Quarter 2025 Results (2Q25)Sales 2Q25 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices U.S. 4,276957811—2,503 International 6,8661,2551,3621,3832,866 Total reported 11,1422,2122,1731,3835,369 % Change vs. 2Q24U.S. 8.72.6(0.1)n/a14.6 International 6.63.1(1.5)6.912.4 Total reported 7.42.9(1.0)6.913.4 Impact of foreign exchange 0.5(0.5)0.4(0.8)1.2 Organic 6.93.4(1.4)7.712.2 Impact of COVID-19 testing sales 1 (0.6)—(2.2)—— Organic (excluding COVID-19 tests) 7.53.40.87.712.2 Organic U.S. 8.72.6(0.1)n/a14.6 International 5.84.0(2.2)7.710.1 First Half 2025 Results (1H25)Sales 1H25 ($ in millions) Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices U.S. 8,4441,9121,682—4,842 International 13,0562,4462,5452,6435,422 Total reported 21,5004,3584,2272,64310,264 % Change vs. 1H24U.S. 8.55.6(3.5)n/a14.8 International 3.91.6(4.5)4.99.1 Total reported 5.73.3(4.1)4.911.7 Impact of foreign exchange (1.1)(1.5)(0.9)(2.9)(0.7) Impact of business exit* (0.1)(0.3)——— Organic 6.95.1(3.2)7.812.4 Impact of COVID-19 testing sales 2 (1.0)—(3.9)—— Organic (excluding COVID-19 tests) 7.95.10.77.812.4 Organic U.S. 8.76.4(3.5)n/a14.8 International 5.84.1(3.0)7.810.3 Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue. *Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024. NutritionSecond Quarter 2025 Results (2Q25)Sales 2Q25 ($ in millions) TotalPediatricAdult U.S. 957587370 International 1,255467788 Total reported 2,2121,0541,158 % Change vs. 2Q24U.S. 2.64.20.2 International 3.1(5.7)9.2 Total reported 2.9(0.4)6.1 Impact of foreign exchange (0.5)(0.6)(0.5) Organic 3.40.26.6 U.S. 2.64.20.2 International 4.0(4.5)9.8 Worldwide Nutrition sales increased 2.9 percent on a reported basis and 3.4 percent on an organic basis in the second quarter. Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1 percent on a reported basis and 6.6 percent on an organic basis, led by strong growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, Abbott's market-leading brand of products designed to meet the nutritional requirements for people with diabetes. First Half 2025 Results (1H25)Sales 1H25 ($ in millions) TotalPediatricAdult U.S. 1,9121,175737 International 2,4469201,526 Total reported 4,3582,0952,263 % Change vs. 1H24U.S. 5.69.00.6 International 1.6(7.0)7.7 Total reported 3.31.35.3 Impact of foreign exchange (1.5)(1.2)(1.6) Impact of business exit* (0.3)—(0.7) Organic 5.12.57.6 U.S. 6.49.02.4 International 4.1(4.6)10.2*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024. DiagnosticsSecond Quarter 2025 Results (2Q25)Sales 2Q25 ($ in millions) TotalCore LaboratoryMolecularPoint of CareRapidDiagnostics U.S. 81135135104321 International 1,3621,0078844223 Total reported 2,1731,358123148544 % Change vs. 2Q24U.S. (0.1)7.35.5(2.0)(7.1) International (1.5)0.5(5.6)(11.9)(6.1) Total reported (1.0)2.2(2.7)(5.1)(6.7) Impact of foreign exchange 0.40.60.70.10.1 Organic (1.4)1.6(3.4)(5.2)(6.8) U.S. (0.1)7.35.5(2.0)(7.1) International (2.2)(0.3)(6.5)(12.1)(6.3) Global Diagnostics sales decreased 1.0 percent on a reported basis, decreased 1.4 percent on an organic basis, and increased 0.8 percent when excluding COVID-19 testing-related sales1. Diagnostics sales growth was impacted by the year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China. COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million in the second quarter of the prior year. Global Core Laboratory Diagnostics sales increased 2.2 percent on a reported basis and increased 1.6 percent on an organic basis. Growth in the quarter was impacted by volume-based procurement programs in China. First Half 2025 Results (1H25)Sales 1H25 ($ in millions) TotalCore LaboratoryMolecularPoint of CareRapidDiagnostics U.S. 1,68268375204720 International 2,5451,85217086437 Total reported 4,2272,5352452901,157 % Change vs. 1H24U.S. (3.5)7.2—(0.3)(12.8) International (4.5)(2.4)(6.1)(4.5)(12.3) Total reported (4.1)0.1(4.4)(1.6)(12.6) Impact of foreign exchange (0.9)(1.2)(1.0)(0.4)(0.6) Organic (3.2)1.3(3.4)(1.2)(12.0) U.S. (3.5)7.2—(0.3)(12.8) International (3.0)(0.7)(4.9)(3.3)(10.7) Established PharmaceuticalsSecond Quarter 2025 Results (2Q25)Sales 2Q25 ($ in millions) TotalKey EmergingMarketsOther U.S. ——— International 1,3831,059324 Total reported 1,3831,059324 % Change vs. 2Q24U.S. n/an/an/a International 6.97.35.9 Total reported 6.97.35.9 Impact of foreign exchange (0.8)(1.4)1.4 Organic 7.78.74.5 U.S. n/an/an/a International 7.78.74.5 Established Pharmaceuticals sales increased 6.9 percent on a reported basis and 7.7 percent on an organic basis in the second quarter. Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 7.3 percent on a reported basis and 8.7 percent on an organic basis, led by double-digit growth in several countries across Asia, Latin America and the Middle East. First Half 2025 Results (1H25)Sales 1H25 ($ in millions) TotalKey Emerging MarketsOther U.S. ——— International 2,6432,024619 Total reported 2,6432,024619 % Change vs. 1H24U.S. n/an/an/a International 4.95.72.4 Total reported 4.95.72.4 Impact of foreign exchange (2.9)(3.3)(1.4) Organic 7.89.03.8 U.S. n/an/an/a International 7.89.03.8 Medical DevicesSecond Quarter 2025 Results (2Q25)Sales 2Q25 ($ in millions) TotalRhythmManagementElectro- physiologyHeart FailureVascularStructuralHeartNeuro-modulationDiabetesCare U.S. 2,503340322282283289193794 International 2,86633337886474347611,187 Total reported 5,3696737003687576362541,981 % Change vs. 2Q24U.S. 14.616.512.215.83.012.20.424.5 International 12.45.710.911.25.413.720.417.5 Total reported 13.410.911.514.74.513.04.620.2 Impact of foreign exchange 1.21.11.20.71.01.30.31.7 Organic 12.29.810.314.03.511.74.318.5 U.S. 14.616.512.215.83.012.20.424.5 International 10.13.68.88.43.811.418.714.7 Worldwide Medical Devices sales increased 13.4 percent on a reported basis and 12.2 percent on an organic basis in the second quarter. Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart and Electrophysiology. Several products contributed to the strong performance, including FreeStyle Libre®, Navitor®, TriClip® and AVEIR®. In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4 percent on a reported basis and 19.6 percent on an organic basis. First Half 2025 Results (1H25)Sales 1H25 ($ in millions) TotalRhythm ManagementElectro- physiologyHeartFailureVascularStructuralHeartNeuro-modulationDiabetesCare U.S. 4,8426446215445515713691,542 International 5,4226147081639166421132,266 Total reported 10,2641,2581,3297071,4671,2134823,808 % Change vs. 1H24U.S. 14.814.411.713.24.216.3(1.1)25.7 International 9.11.27.612.63.59.318.513.8 Total reported 11.77.69.513.13.812.52.918.4 Impact of foreign exchange (0.7)(0.4)(0.6)(0.2)(0.7)(0.7)(0.4)(0.7) Organic 12.48.010.113.34.513.23.319.1 U.S. 14.814.411.713.24.216.3(1.1)25.7 International 10.32.08.813.44.810.520.515.0 ABBOTT'S FINANCIAL GUIDANCEAbbott projects full-year 2025 organic sales growth, excluding COVID-19 testing related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales. Abbott projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales. Abbott projects full-year 2025 adjusted diluted earnings per share of $5.10 to $5.20 and third-quarter 2025 adjusted diluted earnings per share of $1.28 to $1.32. Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP. ABBOTT DECLARES 406th CONSECUTIVE QUARTERLY DIVIDENDOn June 13, 2025, the board of directors of Abbott declared the company's quarterly dividend of $0.59 per share. Abbott's cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at and on LinkedIn, Facebook, Instagram, X and YouTube. Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day. — Private Securities Litigation Reform Act of 1995 —A Caution Concerning Forward-Looking Statements Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 1. In the second quarter of 2025, total worldwide sales were $11.142 billion, total Diagnostics sales were $2.173 billion and COVID-19 testing-related sales were $55 million. In the second quarter of 2024, total worldwide sales were $10.377 billion, total Diagnostics sales were $2.195 billion and COVID-19 testing-related sales were $102 million. 2. In the first half of 2025, total worldwide sales were $21.500 billion, total Diagnostics sales were $4.227 billion and COVID-19 testing-related sales were $139 million. In the first half of 2024, total worldwide sales were $20.341 billion, total Diagnostics sales were $4.409 billion and COVID-19 testing-related sales were $306 million. Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Second Quarter Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 2Q252Q24% ChangeNet Sales $11,142$10,3777.4 Cost of products sold, excluding amortization expense 4,8544,6035.5Amortization of intangible assets 420471(10.7)Research and development 7256983.9Selling, general, and administrative 3,0912,9365.3Total Operating Cost and Expenses 9,0908,7084.4 Operating Earnings 2,0521,66923.0 Interest expense, net 5058(14.2)Net foreign exchange (gain) loss (11)(6)55.6Other (income) expense, net (137)10n/mEarnings before taxes 2,1501,60733.8Taxes on earnings 37130521.3 1)Net Earnings $1,779$1,30236.7 Net Earnings excluding Specified Items, as described below $2,213$2,00310.5 2)Diluted Earnings per Common Share $1.01$0.7436.5 Diluted Earnings per Common Share, excluding Specified Items, as described below $1.26$1.1410.5 2)Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,7511,751 NOTES: See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. n/m = Percent change is not meaningful. See footnotes on the following section.1) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years. 2) 2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $701 million, or $0.40 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses. Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings First Half Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 1H251H24% ChangeNet Sales $21,500$20,3415.7 Cost of products sold, excluding amortization expense 9,3229,0662.8Amortization of intangible assets 840943(10.8)Research and development 1,4411,3824.3Selling, general, and administrative 6,1525,8954.4Total Operating Cost and Expenses 17,75517,2862.7 Operating Earnings 3,7453,05522.6 Interest expense, net 99119(16.4)Net foreign exchange (gain) loss (18)(6)n/mOther (income) expense, net (264)(101)n/mEarnings before taxes 3,9283,04329.1Taxes on earnings 82451659.5 1)Net Earnings $3,104$2,52722.9 Net Earnings excluding Specified Items, as described below $4,132$3,73210.7 2)Diluted Earnings per Common Share $1.77$1.4422.9 Diluted Earnings per Common Share, excluding Specified Items, as described below $2.35$2.1210.8 2)Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,7491,750 NOTES: See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. n/m = Percent change is not meaningful. See footnotes on the following section. 1) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years. 2) 2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.028 billion, or $0.58 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.205 billion, or $0.68 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses. Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information Second Quarter Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 2Q25As Reported(GAAP)SpecifiedItemsAs Adjusted Intangible Amortization $ 420$ (420)$ — Gross Margin 5,8684786,346 R&D 725(20)705 SG&A 3,091(1)3,090 Other (income) expense, net (137)(1)(138) Earnings before taxes 2,1505002,650 Taxes on Earnings 37166437 Net Earnings 1,7794342,213 Diluted Earnings per Share $ 1.01$ 0.25$ 1.26 Specified items reflect intangible amortization expense of $420 million and other net expenses of $80 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.2Q24As Reported(GAAP)SpecifiedItemsAs Adjusted Intangible Amortization $ 471$ (471)$ — Gross Margin 5,3035065,809 R&D 698(41)657 SG&A 2,936(57)2,879 Other (income) expense, net 10(145)(135) Earnings before taxes 1,6077492,356 Taxes on Earnings 30548353 Net Earnings 1,3027012,003 Diluted Earnings per Share $ 0.74$ 0.40$ 1.14 Specified items reflect intangible amortization expense of $471 million and other net expenses of $278 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items. Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information First Half Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) 1H25As Reported(GAAP)SpecifiedItemsAs Adjusted Intangible Amortization $ 840$ (840)$ — Gross Margin 11,33892612,264 R&D 1,441(47)1,394 SG&A 6,152(11)6,141 Other (income) expense, net (264)(36)(300) Earnings before taxes 3,9281,0204,948 Taxes on Earnings 824(8)816 Net Earnings 3,1041,0284,132 Diluted Earnings per Share $ 1.77$ 0.58$ 2.35 Specified items reflect intangible amortization expense of $840 million and other net expenses of $180 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.1H24As Reported(GAAP)SpecifiedItemsAs Adjusted Intangible Amortization $ 943$ (943)$ — Gross Margin 10,3321,02411,356 R&D 1,382(62)1,320 SG&A 5,895(91)5,804 Other (income) expense, net (101)(171)(272) Earnings before taxes 3,0431,3484,391 Taxes on Earnings 516143659 Net Earnings 2,5271,2053,732 Diluted Earnings per Share $ 1.44$ 0.68$ 2.12 Specified items reflect intangible amortization expense of $943 million and other net expenses of $405 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items. A reconciliation of the second-quarter tax rates for 2025 and 2024 is shown below:2Q25($ in millions) Pre-Tax IncomeTaxes on EarningsTax RateAs reported (GAAP) $ 2,150$ 37117.3 % 1) Specified items 50066Excluding specified items $ 2,650$ 43716.5 %2Q24($ in millions) Pre-Tax IncomeTaxes on EarningsTax RateAs reported (GAAP) $ 1,607$ 30519.0 % 2) Specified items 74948Excluding specified items $ 2,356$ 35315.0 %1) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 2) 2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years. A reconciliation of the year-to-date tax rates for 2025 and 2024 is shown below:1H25($ in millions) Pre-Tax IncomeTaxes on EarningsTax RateAs reported (GAAP) $ 3,928$ 82421.0 % 3) Specified items 1,020(8)Excluding specified items $ 4,948$ 81616.5 %1H24($ in millions) Pre-Tax IncomeTaxes on EarningsTax RateAs reported (GAAP) $ 3,043$ 51617.0 % 4) Specified items 1,348143Excluding specified items $ 4,391$ 65915.0 %3) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 4) 2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years. Abbott Laboratories and Subsidiaries Non-GAAP Revenue Reconciliation First Half Ended June 30, 2025 and 2024 ($ in millions) (unaudited)1H251H24% Change vs. 1H24 Non-GAAP AbbottReportedAbbott Reported Impactfrom businessexit (a) Adjusted RevenueReportedAdjusted Organic Total Company21,50020,341 (13) 20,3285.75.8 6.9 U.S.8,4447,780 (13) 7,7678.58.7 8.7 Intl13,05612,561 — 12,5613.93.9 5.8 Total Nutrition4,3584,218 (13) 4,2053.33.6 5.1 U.S.1,9121,811 (13) 1,7985.66.4 6.4 Intl2,4462,407 — 2,4071.61.6 4.1 Adult Nutrition2,2632,150 (13) 2,1375.36.0 7.6 U.S.737733 (13) 7200.62.4 2.4 Intl1,5261,417 — 1,4177.77.7 10.2 (a) Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024. Abbott Laboratories and Subsidiaries Details of Specified Items Second Quarter Ended June 30, 2025 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a)Restructuring and Cost Reduction Initiatives (b)Intangible AmortizationOther (c)Total Specifieds Gross Margin $ 1$ 55$ 420$ 2$ 478 R&D —(7)—(13)(20) SG&A (3)1—1(1) Other (income) expense, net (1)———(1) Earnings before taxes $ 5$ 61$ 420$ 14500 Taxes on Earnings (d) 66 Net Earnings $ 434 Diluted Earnings per Share $ 0.25 The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products. d) Reflects the net tax benefit associated with the specified items and the recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Abbott Laboratories and Subsidiaries Details of Specified Items Second Quarter Ended June 30, 2024 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a)Restructuring and Cost Reduction Initiatives (b)Intangible AmortizationOther (c)Total Specifieds Gross Margin $ 1$ 32$ 471$ 2$ 506 R&D (1)1—(41)(41) SG&A (11)(10)—(36)(57) Other (income) expense, net (147)——2(145) Earnings before taxes $ 160$ 41$ 471$ 77749 Taxes on Earnings (d) 48 Net Earnings $ 701 Diluted Earnings per Share $ 0.40 The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." a) Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the MDR and IVDR requirements for previously approved products and an intangible asset impairment charge. d) Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. Abbott Laboratories and Subsidiaries Details of Specified Items First Half Ended June 30, 2025 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a)Restructuring and Cost Reduction Initiatives (b)Intangible AmortizationOther (c)Total Specifieds Gross Margin $ 1$ 81$ 840$ 4$ 926 R&D (1)(23)—(23)(47) SG&A (6)(6)—1(11) Other (income) expense, net (25)——(11)(36) Earnings before taxes $ 33$ 110$ 840$ 371,020 Taxes on Earnings (d) (8) Net Earnings $ 1,028 Diluted Earnings per Share $ 0.58 The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments. d) Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Abbott Laboratories and Subsidiaries Details of Specified Items First Half Ended June 30, 2024 (in millions, except per share data) (unaudited) Acquisition or Divestiture- related (a)Restructuring and Cost Reduction Initiatives (b)Intangible AmortizationOther (c)Total Specifieds Gross Margin $ 2$ 74$ 943$ 5$ 1,024 R&D (4)(1)—(57)(62) SG&A (25)(19)—(47)(91) Other (income) expense, net (135)——(36)(171) Earnings before taxes $ 166$ 94$ 943$ 1451,348 Taxes on Earnings (d) 143 Net Earnings $ 1,205 Diluted Earnings per Share $ 0.68 The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." a) Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. c) Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments. d) Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. View original content: SOURCE Abbott Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Immuron - FY25 global sales exceed projection, up 49% on prior year
Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior year June 2025 Quarter AUD$1.5 million up 58% on prior year North America Annual sales AUD$2.0 million up 76% on prior year June 2025 Quarter AUD$0.5 million up 49% on prior year MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) Palumbo, Chief Commercial Officer, said, 'Immuron has exceeded sales projections and achieved record FY25 sales of A$7.3 million, with growth just shy of 50% on last year. In FY25, we set out to make Travelan the must-have travel essential for consumers and retailers. This is a fantastic result, supporting our clear growth strategy. Australia, on the back of increased consumer engagement and a clear pharmacy visibility program, achieved annual sales of A$5.2 million, growth of 40% on last year. Travelan is now one of the fastest growing brands in pharmacy in Australia. Our North American business continues to produce record results with strong USA sales to Amazon with improved, more targeted communication focused on the benefits of Travelan driving more users into the brand. This, together with establishing good distribution of Travelan in Canada, resulted in North American sales of A$2 million, growth of 76% on last year. We have achieved record Travelan sales in all markets. In FY26, we will invest to grow in North America while continuing the momentum in Australia.' This release has been authorised by the directors of Immuron Limited. Steven LydeamoreChief Executive Officersteve@ About Travelan®Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a purified tablet preparation of hyper-immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with traveler's diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveler's Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveler's Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection. About Traveler's diarrheaTraveler's Diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. About ImmuronImmuron Limited (ASX: IMC, NASDAQ: IMRN) is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. For more information visit: FORWARD-LOOKING STATEMENTS: This press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A photo accompanying this announcement is available at: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
